Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3074)
All Articles published online
|
Apr 21, 2009 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lakatos PL. Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun? World J Gastroenterol 2009; 15(15): 1799-1804 [PMID: 19370774 DOI: 10.3748/wjg.15.1799] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i15/1799.htm |
| Number | Citing Articles |
| 1 |
Bei Ye, Daniel R van Langenberg. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 137-144 doi: 10.4292/wjgpt.v6.i4.137
|
| 2 |
Riadh Jazrawi. Can more be done to optimise the effect of mesalazine for IBD patients with mild to moderate ulcerative colitis?. Gastrointestinal Nursing 2024; 22(Sup3a): S1 doi: 10.12968/gasn.2024.22.Sup3a.S1
|
| 3 |
Yellela S. R. Krishnaiah, Mansoor A. Khan. Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer. Pharmaceutical Development and Technology 2012; 17(5): 521 doi: 10.3109/10837450.2012.696268
|
| 4 |
Eriko Yasutomi, Sakiko Hiraoka, Shumpei Yamamoto, Shohei Oka, Mami Hirai, Yasushi Yamasaki, Toshihiro Inokuchi, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, Jun Kato, Hiroyuki Okada. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. Journal of Clinical Medicine 2019; 8(12): 2109 doi: 10.3390/jcm8122109
|
| 5 |
Glenn Lemmens, Arno Van Camp, Stephanie Kourula, Tim Vanuytsel, Patrick Augustijns. Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring. Pharmaceutics 2021; 13(2): 161 doi: 10.3390/pharmaceutics13020161
|
| 6 |
N. Weiler, I. Thrun, M. Eberlin, D. Foltys, M. Heise, M. Hoppe-Lotichius, T. Zimmermann, I. Kraemer, G. Otto. Tacrolimus Effects and Side Effects After Liver Transplantation: Is There a Difference Between Immediate and Extended Release?. Transplantation Proceedings 2013; 45(6): 2321 doi: 10.1016/j.transproceed.2013.03.039
|
| 7 |
L. Peyrin-Biroulet, M. Lémann. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2011; 33(8): 870 doi: 10.1111/j.1365-2036.2011.04599.x
|
| 8 |
Wolfgang Kruis, Ludger Leifeld, Julia Morgenstern, Roland Pfützer, Birgitta Reimers, Sabine Ceplis-Kastner. The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: An observational study. Journal of Crohn's and Colitis 2013; 7(4): e125 doi: 10.1016/j.crohns.2012.07.004
|
| 9 |
Riadh Jazrawi. Can more be done to optimise the effect of mesalazine for IBD patients with mild to moderate ulcerative colitis?. Gastrointestinal Nursing 2024; 22(Sup3): S1 doi: 10.12968/gasn.2024.22.Sup3.S1
|